Samsara BioCapital GP, LLC - 09 Nov 2023 Form 3 Insider Report for CARGO Therapeutics, Inc. (CRGX)

Role
10%+ Owner
Signature
Samsara BioCapital GP, LLC, By /s/ Srinivas Akkaraju, Managing Member
Issuer symbol
CRGX
Transactions as of
09 Nov 2023
Net transactions value
$0
Form type
3
Filing time
09 Nov 2023, 18:29:16 UTC
Previous filing
18 Oct 2023
Next filing
16 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CRGX Common Stock 73,700 09 Nov 2023 By Samsara BioCapital, L.P. F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CRGX Series Seed convertible preferred stock 09 Nov 2023 Common Stock 663,300 By Samsara BioCapital, L.P. F1, F2, F3
holding CRGX Series A-1 convertible preferred stock 09 Nov 2023 Common Stock 884,400 By Samsara BioCapital, L.P. F1, F2, F3
holding CRGX Series A-2 convertible preferred stock 09 Nov 2023 Common Stock 1,833,623 By Samsara BioCapital, L.P. F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects a 1-for-13.5685 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement on November 3, 2023.
F2 Shares are held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
F3 Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock will automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.